Nantahala Capital Management - Q2 2021 holdings

$3.52 Billion is the total value of Nantahala Capital Management's 121 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 80.0% .

 Value Shares↓ Weighting
TLT BuyISHARES TRput$173,220,000
+113.1%
1,200,000
+100.0%
4.92%
+107.2%
IWO NewISHARES TRput$93,507,000300,000
+100.0%
2.66%
QURE BuyUNIQURE NVcall$64,862,000
+28.4%
2,105,900
+40.4%
1.84%
+24.8%
MLHR NewMILLER HERMAN INC$64,406,0001,366,266
+100.0%
1.83%
CASH BuyMETA FINL GROUP INC$54,373,000
+21.5%
1,073,936
+8.7%
1.54%
+18.1%
QURE BuyUNIQURE NV$54,293,000
-3.7%
1,762,766
+5.4%
1.54%
-6.3%
XBI NewSPDR SER TRput$54,160,000400,000
+100.0%
1.54%
IMAX BuyIMAX CORP$47,117,000
+61.4%
2,191,490
+50.9%
1.34%
+57.0%
SNDX BuySYNDAX PHARMACEUTICALS INC$44,528,000
-0.5%
2,593,337
+29.5%
1.26%
-3.4%
DXPE BuyDXP ENTERPRISES INC$42,597,000
+11.7%
1,279,183
+1.2%
1.21%
+8.6%
TDOC BuyTELADOC HEALTH INCput$39,910,000
+119.6%
240,000
+140.0%
1.13%
+113.6%
SBTX BuySILVERBACK THERAPEUTICS INC$39,115,000
-8.4%
1,266,266
+27.6%
1.11%
-11.0%
IMTX BuyIMMATICS N.V$29,543,000
+7.9%
2,544,622
+4.2%
0.84%
+4.9%
ALTG BuyALTA EQUIPMENT GROUP INC$27,302,000
+3.7%
2,054,289
+1.4%
0.78%
+0.8%
IMXI BuyINTERNATIONAL MNY EXPRESS IN$25,575,000
+12.9%
1,722,240
+14.2%
0.73%
+9.8%
RMR BuyRMR GROUP INCcl a$25,540,000
-3.6%
660,984
+1.8%
0.73%
-6.2%
KROS BuyKEROS THERAPEUTICS INC$25,434,000
-10.2%
598,880
+30.1%
0.72%
-12.7%
MILE BuyMETROMILE INC$25,006,000
-0.1%
2,732,851
+12.3%
0.71%
-3.0%
PTON NewPELOTON INTERACTIVE INCcall$24,804,000200,000
+100.0%
0.70%
MLHR NewMILLER HERMAN INCcall$23,570,000500,000
+100.0%
0.67%
RDVT NewRED VIOLET INC$23,520,0001,000,000
+100.0%
0.67%
BuyDARIOHEALTH CORP$22,717,000
+57.2%
1,063,515
+41.8%
0.64%
+52.8%
BKE NewBUCKLE INCcall$19,900,000400,000
+100.0%
0.56%
AKBA BuyAKEBIA THERAPEUTICS INC$19,595,000
+12.4%
5,170,063
+0.4%
0.56%
+9.2%
BuyAKUMIN INC$19,595,000
-8.3%
6,220,740
+7.7%
0.56%
-10.7%
PWP NewPERELLA WEINBERG PARTNERS$19,431,0001,510,996
+100.0%
0.55%
BBQ NewBBQ HLDGS INC$18,980,0001,000,000
+100.0%
0.54%
PAYO NewPAYONEER GLOBAL INC$18,758,0001,808,889
+100.0%
0.53%
APEN BuyAPOLLO ENDOSURGERY INC$18,772,000
+49.4%
2,317,491
+1.6%
0.53%
+45.2%
CRIS BuyCURIS INC$16,814,000
-10.7%
2,083,536
+25.3%
0.48%
-13.1%
PAYA BuyPAYA HOLDINGS INC$16,465,000
+7.8%
1,494,116
+7.2%
0.47%
+4.7%
RDI BuyREADING INTL INCcl a$16,148,000
+37.3%
2,316,739
+9.3%
0.46%
+33.4%
HLF NewHERBALIFE NUTRITION LTDcall$14,659,000278,000
+100.0%
0.42%
IMAX NewIMAX CORPcall$12,900,000600,000
+100.0%
0.37%
NAUT NewNAUTILUS BIOTECHNOLOGY INC$12,027,0001,190,810
+100.0%
0.34%
AUTL NewAUTOLUS THERAPEUTICS PLCspon ads$11,909,0001,793,500
+100.0%
0.34%
SLNO BuySOLENO THERAPEUTICS INC$11,132,000
+13.0%
9,765,129
+24.9%
0.32%
+9.7%
HOME NewAT HOME GROUP INC$10,499,000285,000
+100.0%
0.30%
FTVIU NewFINTECH ACQUISITION CORP VIunit 06/24/2026$10,090,0001,000,000
+100.0%
0.29%
SRNG NewSOARING EAGLE ACQUISITION CO$9,754,000979,358
+100.0%
0.28%
SRL BuySCULLY ROYALTY LTD$9,481,000
+46.2%
779,349
+4.8%
0.27%
+41.6%
PRTY NewPARTY CITY HOLDCO INCcall$9,330,0001,000,000
+100.0%
0.26%
TSHA BuyTAYSHA GENE THERAPIES INC$9,160,000
+1121.3%
432,072
+1069.2%
0.26%
+1081.8%
ZVO BuyZOVIO INC$8,136,000
-35.2%
3,141,286
+1.6%
0.23%
-37.1%
RGS BuyREGIS CORP MINNput$5,148,000
+2.5%
550,000
+37.5%
0.15%
-0.7%
IKNA BuyIKENA ONCOLOGY INC$4,909,000
-46.5%
349,660
+7.6%
0.14%
-48.1%
ELOX NewELOXX PHARMACEUTICALS INC$4,510,0002,266,287
+100.0%
0.13%
NPCE NewNEUROPACE INC$3,507,000147,404
+100.0%
0.10%
HCAQ BuyHEALTHCOR CATALIO ACQU CORP$3,490,000
+20.1%
354,296
+21.9%
0.10%
+16.5%
KIRK NewKIRKLANDS INCput$3,032,000132,500
+100.0%
0.09%
MILEW BuyMETROMILE INC*w exp 02/09/202$1,234,000
-63.8%
558,296
+6.3%
0.04%
-65.0%
SOACWS NewSUSTAINABLE OPPORTNTS ACQ CO*w exp 99/99/999$1,156,000802,758
+100.0%
0.03%
PWPPW NewPERELLA WEINBERG PARTNERS*w exp 12/31/202$1,112,000400,000
+100.0%
0.03%
PAYOW NewPAYONEER GLOBAL INC*w exp 06/25/202$790,000333,327
+100.0%
0.02%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

About Nantahala Capital Management

Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.

Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.

Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.

Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ISHARES TR42Q3 202327.2%
CODEXIS INC42Q3 20233.9%
PATHWARD FINANCIAL INC35Q3 20236.3%
SCIENTIFIC GAMES CORP34Q3 20225.3%
DOVER MOTORSPORTS INC34Q3 20210.5%
GOLDEN ENTMT INC33Q3 20232.1%
QAD INC32Q3 20212.6%
SCIENTIFIC GAMES CORP31Q4 20217.7%
DOLBY LABORATORIES INC31Q4 20205.6%
LINCOLN EDL SVCS CORP31Q4 20210.7%

View Nantahala Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
Nantahala Capital Management Q2 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AYTU BIOPHARMA, INCJune 16, 20231,086,81219.7%
Acer Therapeutics Inc.February 14, 20231,226,1917.5%
Aeglea BioTherapeutics, Inc.February 14, 20234,611,3027.5%
AKUMIN INC.February 14, 20232,206,9602.5%
ALTA EQUIPMENT GROUP INC.February 14, 20231,188,9853.7%
Apollo Endosurgery, Inc.February 14, 20234,056,6279.9%
Autolus Therapeutics plcFebruary 14, 20237,782,0184.7%
Bioventus Inc.February 14, 20233,168,5745.1%
CATALYST BIOSCIENCES, INC.February 14, 2023438,0551.4%
Drive Shack Inc.February 14, 20236,500,0007.0%

View Nantahala Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-21
42024-03-15
SC 13G2024-03-11
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Nantahala Capital Management's complete filings history.

Compare quarters

Export Nantahala Capital Management's holdings